<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Rigel Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/rigel-pharmaceuticals-inc</link>
<description>Latest news and press releases for Rigel Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 12:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/rigel-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b82c78dffbe2df114dc5.webp</url>
<title>Rigel Pharmaceuticals Inc</title>
<link>https://6ix.com/company/rigel-pharmaceuticals-inc</link>
</image>
<item>
<title>Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-announces-conference-call-and-webcast-to-report-first-quarter-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-announces-conference-call-and-webcast-to-report-first-quarter-2026-financial-results</guid>
<pubDate>Tue, 28 Apr 2026 12:05:00 GMT</pubDate>
<description>Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2026 financial results after market close on Tuesday, May 5, 2026. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.</description>
</item>
<item>
<title>Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology</title>
<link>https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-announces-publication-of-final-arrow-clinical-trial-data-on-gavretor-pralsetinib-in-patients-with-ret-nsclc-in-the-journal-of-clinical-oncology</link>
<guid isPermaLink="true">https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-announces-publication-of-final-arrow-clinical-trial-data-on-gavretor-pralsetinib-in-patients-with-ret-nsclc-in-the-journal-of-clinical-oncology</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>Pralsetinib induced robust and durable responses with a manageable safety profile, reinforcing the benefits of selective RET inhibitors in treating RET</description>
</item>
<item>
<title>Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-provides-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-provides-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Tue, 03 Mar 2026 21:01:00 GMT</pubDate>
<description>Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the fourth quarter and year ended December 31, 2025, including sales of TAVALISSE® (fostamatinib disodium hexahydrate), GAVRETO® (pralsetinib) and REZLIDHIA® (olutasidenib), and recent business progress.</description>
</item>
<item>
<title>Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update</title>
<link>https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-announces-conference-call-and-webcast-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-announces-conference-call-and-webcast-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-update</guid>
<pubDate>Tue, 24 Feb 2026 13:05:00 GMT</pubDate>
<description>Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 3, 2026. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.</description>
</item>
<item>
<title>Rigel Appoints Michael P. Miller to the Board of Directors</title>
<link>https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-appoints-michael-p-miller-130500225</link>
<guid isPermaLink="true">https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-appoints-michael-p-miller-130500225</guid>
<pubDate>Tue, 03 Feb 2026 13:05:00 GMT</pubDate>
<description>Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Michael P. Miller to its Board of Directors. Mr. Miller has more than four decades of experience in commercial and leadership roles in the biotechnology and pharmaceutical industries.</description>
</item>
<item>
<title>Rigel Provides Business Update and 2026 Outlook</title>
<link>https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-provides-business-2026-outlook-130500837</link>
<guid isPermaLink="true">https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-provides-business-2026-outlook-130500837</guid>
<pubDate>Mon, 12 Jan 2026 13:05:00 GMT</pubDate>
<description>Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today provided a business update including preliminary total revenue and net product sales for the fourth quarter of 2025, ongoing activity from the commercial business and development pipeline, and its financial outlook for 2026.</description>
</item>
<item>
<title>Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-pharmaceuticals-inc-announces-inducement-130500168</link>
<guid isPermaLink="true">https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-pharmaceuticals-inc-announces-inducement-130500168</guid>
<pubDate>Fri, 09 Jan 2026 13:05:00 GMT</pubDate>
<description>Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 24,775 stock options and 16,555 restricted stock units to 11 non-executive employees vesting over four year</description>
</item>
<item>
<title>Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-present-44th-annual-j-130500289</link>
<guid isPermaLink="true">https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-present-44th-annual-j-130500289</guid>
<pubDate>Wed, 07 Jan 2026 13:05:00 GMT</pubDate>
<description>Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2026 at 3:00 p.m. PT (6:00 p.m. ET).</description>
</item>
<item>
<title>Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition</title>
<link>https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-presents-updated-data-ongoing-143000222</link>
<guid isPermaLink="true">https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-presents-updated-data-ongoing-143000222</guid>
<pubDate>Sun, 07 Dec 2025 14:30:00 GMT</pubDate>
<description>Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced updated data from its ongoing Phase 1b study evaluating R2891, an oral prodrug of R835, a potent and selective dual inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4), in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (MDS). The data are being presented today in an oral session by Dr. Guillermo Garcia</description>
</item>
<item>
<title>Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-present-piper-sandler-37th-130500080</link>
<guid isPermaLink="true">https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-present-piper-sandler-37th-130500080</guid>
<pubDate>Wed, 26 Nov 2025 13:05:00 GMT</pubDate>
<description>Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will present a company overview at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 8:30 am ET.</description>
</item>
<item>
<title>Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology</title>
<link>https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-announces-publication-final-5-130500019</link>
<guid isPermaLink="true">https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-announces-publication-final-5-130500019</guid>
<pubDate>Mon, 17 Nov 2025 13:05:00 GMT</pubDate>
<description>Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced a peer-reviewed publication in the Journal of Hematology & Oncology of the final five-year data from the pivotal cohort of the Phase 2 registrational trial evaluating REZLIDHIA® (olutasidenib) for the treatment of patients with relapsed or refractory (R/R) mutant isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML). REZLIDHIA is a potent, se</description>
</item>
<item>
<title>Rigel to Present at the Jefferies Global Healthcare Conference in London</title>
<link>https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-present-jefferies-global-healthcare-130500592</link>
<guid isPermaLink="true">https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-present-jefferies-global-healthcare-130500592</guid>
<pubDate>Wed, 12 Nov 2025 13:05:00 GMT</pubDate>
<description>Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 10:00 a.m. GMT (5:00 a.m. ET).</description>
</item>
<item>
<title>Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-reports-third-quarter-2025-210100261</link>
<guid isPermaLink="true">https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-reports-third-quarter-2025-210100261</guid>
<pubDate>Tue, 04 Nov 2025 21:01:00 GMT</pubDate>
<description>Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the third quarter ended September 30, 2025, including sales of TAVALISSE® (fostamatinib disodium hexahydrate), GAVRETO® (pralsetinib) and REZLIDHIA® (olutasidenib), and recent business progress.</description>
</item>
<item>
<title>Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition</title>
<link>https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-announces-one-oral-four-140500524</link>
<guid isPermaLink="true">https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-announces-one-oral-four-140500524</guid>
<pubDate>Mon, 03 Nov 2025 14:05:00 GMT</pubDate>
<description>Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that data from the ongoing Phase 1b study of R2891, a potent and selective inhibitor of dual interleukin receptor-associated kinases 1 and 4 (IRAK1/4), in patients with lower-risk myelodysplastic syndrome (MDS) who are relapsed or refractory (R/R) to prior therapies will be presented in an oral session at the 67th American Society of Hematology (ASH) A</description>
</item>
<item>
<title>Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update</title>
<link>https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-announces-conference-call-webcast-120500521</link>
<guid isPermaLink="true">https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-announces-conference-call-webcast-120500521</guid>
<pubDate>Wed, 29 Oct 2025 12:05:00 GMT</pubDate>
<description>Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2025 financial results after market close on Tuesday, November 4, 2025. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.</description>
</item>
<item>
<title>Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS</title>
<link>https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-announces-first-patient-enrolled-120500557</link>
<guid isPermaLink="true">https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-announces-first-patient-enrolled-120500557</guid>
<pubDate>Wed, 08 Oct 2025 12:05:00 GMT</pubDate>
<description>Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the first patient has been enrolled in the dose expansion phase of the ongoing Phase 1b study of R2891 in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (MDS). R289 is Rigel's potent and selective dual inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4).</description>
</item>
<item>
<title>Rigel to Participate in Upcoming September Investor Conferences</title>
<link>https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-participate-upcoming-september-investor-120500458</link>
<guid isPermaLink="true">https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-participate-upcoming-september-investor-120500458</guid>
<pubDate>Tue, 26 Aug 2025 12:05:00 GMT</pubDate>
<description>Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and chief executive officer, and Dean Schorno, the company's chief financial officer, will participate in the following investor conferences in September:</description>
</item>
<item>
<title>Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-reports-second-quarter-2025-200100810</link>
<guid isPermaLink="true">https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-reports-second-quarter-2025-200100810</guid>
<pubDate>Tue, 05 Aug 2025 20:01:00 GMT</pubDate>
<description>Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the second quarter ended June 30, 2025, including sales of TAVALISSE® (fostamatinib disodium hexahydrate), GAVRETO® (pralsetinib) and REZLIDHIA® (olutasidenib), and recent business progress.</description>
</item>
<item>
<title>Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update</title>
<link>https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-announces-conference-call-webcast-120500628</link>
<guid isPermaLink="true">https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-announces-conference-call-webcast-120500628</guid>
<pubDate>Tue, 29 Jul 2025 12:05:00 GMT</pubDate>
<description>Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2025 financial results after market close on Tuesday, August 5, 2025. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.</description>
</item>
<item>
<title>Rigel to Present at the Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-present-jefferies-global-healthcare-120500104</link>
<guid isPermaLink="true">https://6ix.com/company/rigel-pharmaceuticals-inc/news/rigel-present-jefferies-global-healthcare-120500104</guid>
<pubDate>Wed, 28 May 2025 12:05:00 GMT</pubDate>
<description>Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 12:50 p.m. ET in New York, NY.</description>
</item>
</channel>
</rss>